TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04466280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200 mg of hydroxychloroquine daily for participants in the intervention group 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucodentol
Description: Intervention Group 2 participants will place a thin layer of Dentol gel in the vestibular area of the mouth every 6 to 8 hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personal protective equipment
Description: Personal protective equipment such as masks, gloves, protective shields

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personal protective equipment
Description: Personal protective equipment such as masks, gloves, protective shields

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personal protective equipment
Description: Personal protective equipment such as masks, gloves, protective shields
Study: NCT03214224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: remote pulmonary function testing
Description: Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard pulmonary function testing
Description: Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
Study: NCT03957044

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The education of sensory integration with vestibular education
Description: Tactical, proprioceptive, visual and auditory senses were used in sensory integrity training sessions. In this group, the training program on tactile, proprioceptive, visual and auditory sensory activities was carried out for 2 weeks and 40 minutes. Sensory integrity training was performed by the physiotherapist and in the sensory room.~At the end of the training sessions, mothers were informed about the application of sensory integrity training to daily activities.Sensory integrity therapy room added tactile, proprioceptive, visual and auditory sensory materials as well as materials for vestibular sensation. Vestibular sensory materials, skateboard, swing, hammock, bowl, ball, ball pool, slide, climbing bar, trampoline, and balance board were used.
Study: NCT03509064

Intervention type: OTHER
Intervention: Collection sheet
Description: Using EQ5D questionnaire and a collection of care resources consumed by the patients during a period of 6 months associated by using validated scales (SF36, DN4, PROFAD SSI, ESPRI) : collection sheet

Intervention type: OTHER
Intervention: Collection sheet
Description: Using EQ5D questionnaire and a collection of care resources consumed by the patients during a period of 6 months associated by using validated scales (SF36, DN4, PROFAD SSI, ESPRI) : collection sheet
Study: NCT03076892

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aktilite® Galderma
Description: preparation of the lesions, Metvixia application + occlusive dressing during 3 hours + illumination: 7 to 10 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHOS ISTOS PDT
Description: preparation of the lesions, Metvixia application + occlusive dressing during 30 minutes + illumination: 2.5 hours
Study: NCT03630497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of BN201 treatment with Placebo
Description: Single Dose or Multiple Dose of BN201 IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of BN201 treatment with Placebo
Description: Single Dose or Multiple Dose of BN201 IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of BN201 treatment with Placebo
Description: Single Dose or Multiple Dose of BN201 IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of BN201 treatment with Placebo
Description: Single Dose or Multiple Dose of BN201 IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of BN201 treatment with Placebo
Description: Single Dose or Multiple Dose of BN201 IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of BN201 treatment with Placebo
Description: Single Dose or Multiple Dose of BN201 IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of BN201 treatment with Placebo
Description: Single Dose or Multiple Dose of BN201 IV administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparison of BN201 treatment with Placebo
Description: Single Dose or Multiple Dose of BN201 IV administration
Study: NCT04560712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture Therapy
Description: Undergo acupuncture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Undergo usual care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Undergo usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03183791

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RELAXaHEAD app
Description: The Research Volunteers (RV) will explain the rationale for PMR and load the RELAXaHEAD app onto the patients' smartphones. The RV will review the app with the subject, focusing on user knowledge, usability, and engagement. The patient will perform a 15 minute session of PMR during the study enrollment and discuss the optimal time and place to practice PMR at home. Subjects will also be taught to enter their headache log daily on the app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Monitored Usual Care (MUC)
Description: The Research Volunteers (RV) will load the app onto the patients' smartphones but the PMR component will be blocked on the version of the app that the MUC patients receive.~Subjects will be taught to enter their headache log daily on the app.
Study: NCT04471584

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of ILR device
Description: All patients enrolled will be randomized to have one of three ILR devices implanted (BIOMONITOR III, Reveal LinQ, or Confirm RX) and will be given event monitoring device for concurrent evaluation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of ILR device
Description: All patients enrolled will be randomized to have one of three ILR devices implanted (BIOMONITOR III, Reveal LinQ, or Confirm RX) and will be given event monitoring device for concurrent evaluation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insertion of ILR device
Description: All patients enrolled will be randomized to have one of three ILR devices implanted (BIOMONITOR III, Reveal LinQ, or Confirm RX) and will be given event monitoring device for concurrent evaluation.
Study: NCT01403103

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative studies
Study: NCT02949219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT01806259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg IV
Description: Active drug
Study: NCT02459691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vida Sana
Description: Vida Sana is a Diabetes Prevention Program-based, culturally-adapted intervention that will have 2 distinct stages: The intensive treatment stage will implement a culturally adapted year-long Group Lifestyle Balance curriculum. The curriculum uses a goal-based approach to promote positive outcome expectancies and foster self-efficacy. The maintenance stage will be focused on (1) facilitating continued behavior change; (2) fostering participants' self-efficacy and independence; and (3) reinforcing problem-solving and behavior maintenance skills. These will be done via secure e-messaging.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Only
Description: Patients assigned to this group will continue medical care as usual. That is, they will continue to see their primary care provider and any specialist he/she may recommend. They may also access additional health education resources available at the Palo Alto Medical Foundation. They will continue to receive general age and gender-appropriate reminders of health maintenance tests/exams and immunizations, per Palo Alto Medical Foundation standard practice.
Study: NCT01806259

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo looking like the Active drug
Study: NCT03127228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard mechanical debridement
Description: Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with dental scalers prior to bone grafting regenerative therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Standard mechanical debridement
Description: Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with dental scalers prior to bone grafting regenerative therapy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG laser-assisted debridement
Description: Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with the aid of the laser prior to bone grafting regenerative therapy
Study: NCT01160770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobazam
Description: Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
Study: NCT03380039

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR-BCMA T cells
Description: Single dose of CAR-BCMA T cells will be infused, and classic 3+3 dose escalation will be applied.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion.
Study: NCT01728467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVX000222
Description: capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, RVX000222
Description: capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
Study: NCT00087633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 135 micrograms subcutaneously (SC) weekly for 4 weeks followed by 180 micrograms SC weekly for 44 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 400 mg orally (PO) daily escalating to 1200 mg PO daily, for 48 weeks
Study: NCT03026673

Intervention type: OTHER
Intervention: NSAID use
Description: The purpose of the study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
Study: NCT00575744

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Sentinel Node Biopsy
Description: Once the patient is asleep under anesthetic, they receive an intraoperative injection of 1.0 mCi of Technetium-99 sulfur colloid into normal breast tissue surrounding the primary cancer or biopsy cavity directed subareolar or around the tumor. This is followed by blue dye injected in the subareolar complex approximately 5 minutes prior to incision. The sentinel node biopsy is performed, followed by lumpectomy/mastectomy, and a completion axillary node dissection if the sentinel node(s) were positive.
Study: NCT03575832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Complete nutrition counseling sessions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive an exercise plan and printed materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive telephone coaching calls
Study: NCT04035772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wiki101 and WikiTrauma
Description: Wiki101 is a theory-based continuing professional development course to teach healthcare professionals how to use WikiTrauma. WikiTrauma is a wiki containing implementation tools built upon the Google Sites platform.
Study: NCT03976986

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous-flow portable oxygen concentrator (cPOC)
Description: SeQal Eclipse 3® on continuous-flow (SeQual,Ball Ground,GA): flow rate 2 litre per minute (lpm).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous-flow portable oxygen concentrator (cPOC)
Description: SeQal Eclipse 3® on continuous-flow (SeQual,Ball Ground,GA): flow rate 2 litre per minute (lpm).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed-flow portable oxygen concentrator (pPOC)
Description: InogenOne G3® (Inogen,Goleta,CA) on pulsed-flow mode: setting 2 (flow rate 420 ml/min, 16.8 ml +/- 3ml per bolus at 25 rpm).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulsed-flow portable oxygen concentrator (pPOC)
Description: InogenOne G3® (Inogen,Goleta,CA) on pulsed-flow mode: setting 2 (flow rate 420 ml/min, 16.8 ml +/- 3ml per bolus at 25 rpm).
Study: NCT00550836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study: NCT04579913

Intervention type: OTHER
Intervention: Review of medical history, administration of questionnaires, uroflowmetry and PVR as measured by ultrasound
Description: Administration of questionnaires to assess patient LUTS, quality of life, sexual behavior and erectile function, in addition to performing PVR and uroflow tests.
Study: NCT00427804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcitriol
Description: 0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose
Study: NCT03374124

Intervention type: DIAGNOSTIC_TEST
Intervention: sinonasal outcome test-22
Description: Evaluate the nasal mucosal inflammation condition and overall quality-of-life of CRS patients
Study: NCT06453993

Intervention type: OTHER
Group type: OTHER
Intervention: Exhaled VOC breath test
Description: To determine longitudinal variation in exhaled VOC concentrations during intended curative therapy for EC cancer.
Study: NCT02944877

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: social media intervention
Description: social media intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social media intervention
Description: social media intervention
Study: NCT02154815

Intervention type: OTHER
Intervention: Questionnaires : Patient-Reported Outcomes
Description: Patient-Reported Outcomes completion every six months prior to surgery, at hospital discharge, and at 3, 6,12, 24, 36, 48, 72 months

Intervention type: OTHER
Intervention: Questionnaires : Patient-Reported Outcomes
Description: Patient-Reported Outcomes completion every six months prior to surgery, at hospital discharge, and at 3, 6,12, 24, 36, 48, 72 months
Study: NCT03680729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Brothers Saving Brothers (aBSB)
Description: This information is listed in the arm description.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Street Outreach
Description: This information is listed in the arm description.
Study: NCT01350427

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine supplementation
Description: 1 bout of resistance exercise and supplementation of 4.0 g of leucine + 5.6 g of alanine

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Description: 1 bout of resistance exercise and supplementation of 4.0 g of leucine + 2.8 g of isoleucine + 2.8 g of valine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alanine supplementation
Description: 1 bout of resistance exercise and supplementation of 9.6 g of alanine
Study: NCT00835497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets
Description: 1 x 5 mg/500 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg/500 mg METAGLIP™ Tablets
Description: 1 x 5 mg/500 mg, single-dose fasting
Study: NCT03832959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EnsoETM
Description: The EnsoETM is a device with a esophageal probe that can provide temperature adjustment
Study: NCT03194646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily for 24 weeks, 2 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen).

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard of care as determined by the investigators (including watch and wait, symptomatic nonhormonal)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily for 12 weeks, 8 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily for 24 weeks, 4 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilaprisan (BAY1002670)
Description: 2 mg of Vilaprisan once daily for 12 weeks, 6 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen)
Study: NCT02622607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride)
Study: NCT04092608

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GDFT
Description: The titration of fluid will be based on stroke volume variation. The goal is to maintain this variable \< 13% during surgery with multiple mini fluid challenge of 100 ml of balanced crystalloid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LOW CVP (restrictive group)
Description: Goal = CVP \< 7mmHg and only 2 ml/kg/h max during surgery.
Study: NCT00194116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium ER
Description: Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: . Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
Study: NCT01060007

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study: NCT02892435

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: incisional negative pressure wound therapy
Description: positioning incisional negative pressure therapy over closed wound.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional dressing
Description: positioning conventional dressing
Study: NCT02025400

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eRehab
Description: Growth in e-Health applications, defined as any computer or Internet application integrated into health services, has resulted in the development of treatment strategies to improve healthcare while reducing costs. The utilization of e-Health to provide a rehabilitative intervention has recently been identified in the cardiac literature as e-rehabilitation or eRehab. This study specifically compares an orthopedic eRehab Internet application to standard outpatient physical therapy as an adjunct in the treatment of non-complicated knee and shoulder disorders.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formal Physical Therapy
Description: This intervention involves referral to a licensed physical therapist or supervised ATC-L.